Surgery Partners is trading 5.49% up at $14.40, with no clear company-specific catalyst identified for September 16, 2026.

  • September 14 coverage included JPMorgan raising its price target while maintaining a Neutral rating.
  • That action does not directly explain the gain.
  • U.S. equity futures are modestly higher, but the broad market move remains below the provided 0.5% threshold.